img

United States Skin Cancer Therapeutics Market By Cancer Type (Melanoma, Non-melanoma, Others), By Type (Diagnosis, {Dermatoscopy, Biopsy, Genetic Tests, Others}, Therapeutics {Chemotherapy, Immunotherapy, Targeted Therapy, Others}), By Region, Competition Forecast & Opportunities, 2028


Published on: 2024-11-15 | No of Pages : 320 | Industry : Healthcare

Publisher : MIR | Format : PDF&Excel

United States Skin Cancer Therapeutics Market By Cancer Type (Melanoma, Non-melanoma, Others), By Type (Diagnosis, {Dermatoscopy, Biopsy, Genetic Tests, Others}, Therapeutics {Chemotherapy, Immunotherapy, Targeted Therapy, Others}), By Region, Competition Forecast & Opportunities, 2028

Forecast Period2024-2028
Market Size (2022)USD 2.85 billion
CAGR (2023-2028)7.24%
Fastest Growing SegmentMelanoma
Largest MarketMid-West

MIR Consumer Healthcare

Market Overview

Key Market Drivers

Rising Cases of Skin Cancer

Advancements in Treatment Modalities


MIR Segment1

Rising Early Detection and Diagnosis

Increasing Immunotherapy Demand

Key Market Challenges

Late-Stage Diagnosis


MIR Regional

Lack of Access to Specialized Care

High Treatment Costs

Key Market Trends

Advancements in Treatment Procedures

Clinical Trials and Research Investment

Segmental Insights

Cancer Type Insights

In 2022, the Skin Cancer Therapeutics Market was dominated by the

Type Insights

In 2022, the Skin Cancer Therapeutics Market was dominated by the Diagnosis segment and is predicted to continue expanding over the coming years.

Regional Insights

In 2022, the United States Skin Cancer Therapeutics Market was dominated by the Mid-West segment and is predicted to continue expanding over the coming years.

Recent Development

  • In March 2022 , Nivolumab andrelatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) were approved by theUS FDA for adult and paediatric patients 12 years of age or older withunresectable or metastatic melanoma. Future market growth is probably beingdriven by the increasing approval of novel immunotherapies.
  • In April 2022, A complete dealfor Regeneron Pharmaceuticals, Inc. to acquire Checkmate by CheckmatePharmaceuticals, Inc. was signed. With this acquisition, Regeneron hopes toadvance the main candidate Vidutolimod, which is presently being researched inconjunction with other drugs for the treatment of head and neck cancer,non-melanoma skin cancers, and melanoma.

Key Market Players

  • AbbottLaboratories
  • Amgen,Inc.
  • PfizerInc.
  • Bristol-MyersSquibb Company
  • F.Hoffmann-La Roche Ltd
  • Merck& Co., Inc.
  • SanofiS.A.
  • SunPharmaceutical Industries Ltd
  • DaiichiSankyo Company, Limited
  • Sirnaomics,Inc.

By Cancer Type

By Type

By Region

  • Melanoma
  • Non-melanoma
  • Others
  • Diagnosis
  • Therapeutics
  •  
  • North-East
  • Mid-west
  • West
  • South

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )
To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )